Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 05/09/24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 02/29/24
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care ConferencePRNewsWire • 02/26/24
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis OrganisationPRNewsWire • 02/08/24
Here's Why Spyre Therapeutics (SYRE) Could be Great Choice for a Bottom FisherZacks Investment Research • 02/06/24
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of DirectorsPRNewsWire • 02/05/24